Global Blood Therapeutics, Inc.
GBT · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $2,096 | $2,246 | $1,888 | $1,603 |
| - Cash | $261 | $392 | $685 | $383 |
| + Debt | $658 | $659 | $660 | $230 |
| Enterprise Value | $2,493 | $2,513 | $1,862 | $1,450 |
| Revenue | $72 | $55 | $56 | $52 |
| % Growth | 29.7% | -1.7% | 7.8% | – |
| Gross Profit | $70 | $54 | $55 | $51 |
| % Margin | 98% | 98.1% | 97.9% | 98.4% |
| EBITDA | -$72 | -$71 | -$80 | -$65 |
| % Margin | -100% | -128.3% | -143.5% | -125% |
| Net Income | -$82 | -$81 | -$91 | -$71 |
| % Margin | -115.3% | -147.6% | -163.1% | -136.4% |
| EPS Diluted | -1.26 | -1.26 | -1.42 | -1.13 |
| % Growth | 0% | 11.3% | -25.7% | – |
| Operating Cash Flow | -$44 | -$72 | -$68 | -$65 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$45 | -$72 | -$69 | -$66 |